Search this site

Exec Summary: HealthTech Founder and M&A Advisor Lloyd Price shares his thoughts with Healthcare Business International's Joe Quiruga alongside Dr Murray Ellender, Dr Leonid Shapiro, Klaus Boehncke on what we think is in store for 2024. "As we kick off the new year, HBI speaks to healthcare market experts across a variety of countries and subsectors, and hears what they think is in store for 2024. An election-heavy year could herald changes – but will any be enough to stave off the challenges of workforce, inflation, and soaring costs?" HBI understands demand for private healthcare is likely to remain high, especially in NHS systems like the UK and Italy. This is good news both for private healthcare services providers, and the B2B businesses which work within the system. Murray Ellender, CEO at digital triage and remote consultations solutions firm eConsult, tells HBI: “I think what you’re seeing is an expansion of private healthcare because of struggles within the NHS. This means more people are turning to private healthcare and demand is ramping up. “But it also means some of the tools used in the NHS to manage demand are now being introduced to the private sector. A theme will be how will the private sector use technology to triage demand. We as a business are looking at how we can support private providers now, which wasn’t the case before.” Leonid Shapiro, managing partner and founder of consultancy Candesic tells HBI: “In 2024, there’s going to be continued evolution in the use of AI in healthcare as people find new uses for it. Of course, computers are getting faster, there’s more data being collected, and more automation using big data.” Klaus Boehncke, digital health lead at L.E.K. consulting, tells HBI: “Hopefully we will have the better economic climate everyone is hoping for which can foster innovation, make it easier to access capital, and allow investors to push forward healthcare technology. There’s a lot of potential in generative AI.” Price adds: “AI’s an interesting one – it will impact services in some areas and not in others. Robotic process automation is starting to do a lot of repetitive tasks for example. When you talk about AI, you tend to think of generative AI, but you will likely see it helping to scan images for example.” A B2B approach is best for digital companies in general, according to both Price and Ellender, with the former saying the investment would be too large to justify a consumer product and Ellender pointing out the direct-to-consumer models like Babylon didn’t work as well as hoped. Source: http://www.healthcarebusinessinternational.com/is-2024-the-year-of-recovery/ Healthcare Business International HBI is where the international health care services industry comes together. HBI delivers unique content on for-profit healthcare services in Europe and Emerging Markets. We run the annual HBI Conference, which is now in it’s 13th year and is the leading global CEO-level conference dedicated to the sector. Our market intelligence focuses on investment and business strategies across twenty health and care sectors with exclusive news, data, analysis and events. Online and in person, HBI helps business professionals at operators, suppliers, investors and their advisors to identify new opportunities, achieve their investment goals, expand their professional networks and gain competitive advantage. https://www.healthcarebusinessinternational.com

What is the federated data platform (FDP)? The Federated Data Platform (FDP) is software that will sit across NHS trusts and integrated care systems allowing them to connect data they already hold in a secure and safe environment. GP data will not be part of the national platform. FDP does not change data controllership arrangements so if there is data sharing agreement between integrate care system (ICS) and GPs locally to share data for care co-ordination then they can use the local version of FDP for that purpose. The software will be ‘federated’ across the NHS. This means that every hospital and integrated care board will have their own version of the platform which can connect and collaborate with other data platforms as a ‘federation’. This makes it easier for health and care organisations to work together, compare data, analyse it at different geographic, demographic and organisational levels and share and spread new effective digital solutions. The federated data platform is not a data collection; it is software that will help to connect disparate sets of data and allow them to be used more effectively for care. Why do we need a federated data platform? The NHS is made up of multiple organisations that use data every day to manage patient care and plan services. Historically, it has been held in different systems that do not speak to each other, creating burden for staff and delays to patient care. It also makes it difficult to work at scale and share information. Better use of data brings big benefits for patients by ensuring more joined up care, greater choice and improved health outcomes, and ultimately saving lives. Feedback from patients has shown that we need to make it easier for staff to access the information they need, freeing up time to invest in delivering the best care possible for patients and facilitating the rollout of innovations taking place across the healthcare system. The Federated Data Platform will provide software to link these NHS trusts and regional systems and give us a consistent technical means of linking data that is already collected for patient care. Clinicians will easily have access to the information they need to do their job – in one place – freeing up time spent on administrative tasks and enabling them to deliver the most appropriate care for patients. GP data will not be part of the national platform. FDP does not change data controllership arrangements so if there is data sharing agreement between integrated care system (ICS) and GPs locally to share data for care co-ordination then they can use the local version of FDP for that purpose. What will the Federated Data Platform do? Every trust and integrated care board will have their own platform, with the capability to connect and share information between them where this is helpful. This could include the number of beds in a hospital, the size of waiting lists for elective care services, staff rosters, or the availability of medical supplies. The Federated Data Platform will initially be focused on supporting 5 key NHS priorities: Elective recovery – to address the backlog of people waiting for appointments or treatments. Care coordination – to enable the effective coordination of care between local health and care organisations and services, reducing the number of long stays in hospital. Vaccination and immunisation – to continue to support the vaccination and immunisation of vulnerable people while ensuring fair and equal access and uptake across different communities. Population health management – to help integrated care systems proactively plan services that meet the needs of their population. Supply chain management – to help the NHS put resources where they are needed most and buy smarter so that we get the best value for money. How will patient data be used? No new data will be collected. Existing data will be used for analysing activity, auditing quality, planning service delivery, and service analysis to improve patient outcomes. For example, Chelsea and Westminster NHS Foundation Trust has used new software in its gynaecology department to track patients with suspected cancer through to diagnosis and first treatment, which has reduced the waiting time for a first appointment by an average of two days and cut the overall time to diagnosis. That’s two days less that patients spent worrying and waiting to find out what the next steps in their treatment will be. North Tees and Hartlepool NHS Foundation Trust is using software to monitor all admitted patients and assess any potential barriers to discharge. The system has freed up almost 10 hours of clinician time each week and resulted in patients going home faster, with long stays (over 21 days) falling by more than a third (36%). How does this fit with Palantir’s Foundry platform, which is currently used? Palantir provides NHS England with data management platform services (Foundry) which were procured to provide the national organisations responsible for coordinating the response to COVID-19 with secure, reliable and timely data – in a way that protects the privacy of our citizens – in order to make informed, effective decisions. We learned huge lessons through our COVID-19 response and started to use data to work smarter – to anticipate the virus, protect the most vulnerable, put resources where they were needed and deliver the largest vaccination programme in NHS history. Such an efficient and effective response was only possible because of investment in digital systems. The opportunity now is to apply what we have learned to both managing our elective recovery and our long-term challenges. The investment in a federated data platform will provide local health and care organisations with a technical architecture that enables them to make the most of the information they hold to transform care and improve outcomes for patients. NHS England has recently awarded a 12 month transition contract to Palantir to support the successful transition from the current Palantir Foundry platform to the new Federated Data Platform and Associated Services (FDP-AS) supplier. The Foundry platform was used during Covid-19 pandemic to support reporting and vaccination programmes, more recently it has also been used to test the viability of a number pilots for FDP. This is to provide the safe and smooth transition and exit service of critical products that were developed to respond to the Covid-19 pandemic (for Covid-19 and elective recovery purposes), to alternative provisions, including the transition of products to the new FDP-AS supplier following completion of the procurement process and contract award. Source: https://www.england.nhs.uk/digitaltechnology/digitising-connecting-and-transforming-health-and-care/fdp-faqs/#how-does-this-fit-with-palantirs-foundry-platform-which-is-currently-used

Exec Summary: In December 2023, SmileDirectClub filed for Chapter 11 bankruptcy and announced plans to shut down its operations. The company cited the ongoing challenges it faced from regulatory scrutiny, lawsuits, and declining sales. While SmileDirectClub's story ended abruptly, the company's impact on the teeth-straightening industry was undeniable. It popularized the concept of at-home teeth straightening and demonstrated the potential of digital health solutions to revolutionize healthcare delivery. The company's legacy will also include the lessons learned about the importance of patient safety, regulatory compliance, and the need for a strong network of healthcare professionals. SmileDirectClub's success has undoubtedly demonstrated the potential of B2C digital health solutions. However, the company's challenges also highlight the need for careful regulation and oversight in this rapidly evolving industry. As B2C digital health continues to expand, companies must prioritize patient safety and transparency in order to maintain public trust and ensure long-term success. The FDA has been increasingly scrutinizing B2C digital health companies, and it is likely to continue to do so as the market grows. Companies that fail to adhere to regulatory requirements and prioritize patient safety could face significant legal and financial repercussions. A Pioneer in Direct-to-Consumer Dental Care SmileDirectClub, founded in 2014, has revolutionized the orthodontic industry by offering clear aligners directly to consumers through an affordable and convenient platform. The company's mission is to make orthodontic care accessible and affordable to millions of people who might otherwise not be able to afford it. Impact on the B2C Digital Health Landscape SmileDirectClub's success has had a significant impact on the B2C digital health industry, paving the way for other companies to offer direct-to-consumer healthcare services. The company's model has been particularly disruptive in the dental care sector, where traditional orthodontists have long dominated the market. Canary in the Coalmine? While SmileDirectClub has been a disruptor in the B2C digital health space, it has also been met with criticism from traditional healthcare providers and regulators. Some critics argue that the company's model may compromise patient safety, as it does not require in-person consultations with orthodontists. Others worry that the company's marketing practices may mislead consumers about the effectiveness and suitability of its clear aligners. The Future of B2C Digital Health The rise of direct-to-consumer healthcare is a trend that is likely to continue in the years to come. As technology advances and consumer expectations evolve, we can expect to see more companies offering convenient, affordable, and personalized healthcare services directly to consumers. However, it is important to ensure that these services are safe, effective, and aligned with the best practices of traditional healthcare providers. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk History of Smile Direct Club SmileDirectClub was a teledentistry company that revolutionized the teeth-straightening industry. It was founded in 2014 by Jordan Katzman and Alex Fenkell, who envisioned a more affordable and accessible way to achieve a beautiful smile. The company introduced a system of clear aligners that could be prescribed and monitored by dentists remotely, eliminating the need for traditional braces and their associated inconveniences. SmileDirectClub's early years were marked by rapid growth and expansion. The company's convenient and affordable services attracted a wide range of customers, and it quickly became the leading provider of at-home teeth straightening in the United States. By 2019, the company had over 2 million satisfied customers and was expanding into international markets. However, SmileDirectClub's success was not without controversy. The company faced criticism from traditional dentists and orthodontists who argued that its teledentistry model was not as effective as traditional orthodontic treatment and posed potential risks to patient safety. The company also came under scrutiny from the FDA, which investigated allegations that its aligners were being prescribed for patients with complex orthodontic needs that were not suitable for at-home treatment. In the face of these challenges, SmileDirectClub made efforts to improve its patient care and regulatory compliance. The company partnered with more dentists and orthodontists to provide in-person consultations and support, and it strengthened its quality control measures. However, these efforts were not enough to overcome the mounting criticism and regulatory pressure. In December 2023, SmileDirectClub filed for Chapter 11 bankruptcy and announced plans to shut down its operations. The company cited the ongoing challenges it faced from regulatory scrutiny, lawsuits, and declining sales. While SmileDirectClub's story ended abruptly, the company's impact on the teeth-straightening industry was undeniable. It popularized the concept of at-home teeth straightening and demonstrated the potential of digital health solutions to revolutionize healthcare delivery. The company's legacy will also include the lessons learned about the importance of patient safety, regulatory compliance, and the need for a strong network of healthcare professionals. Bankruptcy and Controversry Smile Direct Club, a popular online dental care company, filed for Chapter 11 bankruptcy protection in the US in September 2023. The company cited nearly $900 million in debt as the reason for its bankruptcy filing. Despite a months-long search for a partner willing to invest in the company, Smile Direct Club was unable to secure the necessary funding to remain operational. The company officially shut down its global operations on December 11, 2023. The closure of Smile Direct Club has left many customers wondering about the status of their ongoing treatments. The company has stated that it will work with its existing customers to either complete their treatments or provide refunds. Here are some of the factors that contributed to Smile Direct Club's bankruptcy: Increased competition: In recent years, the direct-to-consumer dental care market has become increasingly crowded with competitors. This has made it more difficult for Smile Direct Club to stand out and attract new customers. Negative publicity: Smile Direct Club has been criticized for its aggressive marketing tactics and the quality of its aligners. These criticisms have damaged the company's reputation and made it more difficult for it to retain customers. Regulatory scrutiny: The Federal Trade Commission (FTC) has been investigating Smile Direct Club for allegedly making misleading claims about the effectiveness of its aligners. This investigation has added to the company's legal and financial woes. The closure of Smile Direct Club is a significant setback for the direct-to-consumer dental care industry. It will be interesting to see how the industry evolves in the wake of this bankruptcy. Canary in the B2C Digital Health Coalmine? Smile Club Direct's collapse is certainly a significant event that could signal challenges ahead for the B2C digital health industry. However, it is too early to say definitively whether it will be a "canary in the coal mine" or simply a case of one company's missteps. Smile Club Direct was a direct-to-consumer (DTC) dental plans company that offered affordable dental plans to consumers. The company grew rapidly in recent years, but it also drew criticism for its aggressive marketing tactics and its use of high-pressure sales techniques. In 2023, Smile Club Direct was fined $25 million by the Federal Trade Commission for deceiving consumers about its plans and services. The FTC found that the company had misled consumers about the coverage and limitations of its plans, and that it had used deceptive advertising to pressure consumers into buying plans they didn't need. The FTC's ruling and the subsequent publicity surrounding it damaged Smile Club Direct's reputation and caused many consumers to cancel their plans. The company was forced to lay off employees and close several offices. In April 2023, Smile Club Direct filed for bankruptcy protection. The company cited the FTC's ruling, the COVID-19 pandemic, and increased competition in the DTC dental plans market as factors that contributed to its financial problems. The collapse of Smile Club Direct is a major setback for the DTC digital health industry. The company was one of the leading providers of DTC dental plans, and its downfall could make consumers more wary of signing up for these types of plans. However, it is important to note that Smile Club Direct's problems were specific to the company itself. The company's aggressive marketing tactics and deceptive advertising practices were not the norm for the DTC digital health industry. Overall, while the collapse of Smile Club Direct is a significant event, it is too early to say definitively whether it will be a "canary in the coal mine" for the B2C digital health industry. The industry is still growing rapidly, and there are many legitimate and successful DTC digital health companies. However, the Smile Club Direct case should serve as a reminder to consumers to be wary of DTC companies that engage in aggressive or deceptive marketing practices. Here are some specific lessons that can be learned from Smile Club Direct's collapse: Companies should be transparent about their plans and services. Consumers should be able to easily understand what is covered by a plan and what is not. Companies should avoid using high-pressure sales tactics. Consumers should not feel pressured to buy a plan they don't want or need. Companies should be ethical in their marketing practices. Companies should not make false or misleading claims about their products or services. If DTC digital health companies can learn from Smile Club Direct's mistakes, they can avoid similar problems in the future and continue to grow and innovate. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

HealthInvestor gathered perspectives from industry experts such as Paul Tomasic, Houlihan Lokey, Molly Gilmartin, AlbionVC, Michelle Tempest, Candesic, Neil Mitchell, Rickitt Mitchell and Lloyd Price, Nelson Advisors. They delve into the triumphs and hurdles within the #healthtech investment space. The result is a comprehensive outlook, forecasting anticipated trends and opportunities for 2024! Original Source:: https://lnkd.in/e-NMVt4d Forecasting HealthTech Investment Trends in 2024 This year has posed significant challenges for founders, chief executives, and management teams. Previously instructed to prioritise growth, they now find themselves shifting focus to emphasising on  Annual Recurring Revenue (ARR), EBITDA, and overall profitability. Notable instances, like Babylon's insolvency, highlight the consequences of this shift, especially for companies listed on the stock market, whose fortunes are dictated more by market sentiment and share prices. Looking ahead, a more challenging funding landscape is anticipated for the NHS. However, optimism arises for increased investment in digital health and the broader health sector in the second half of the year. Entering the summer and anticipating the final phase of a UK and US election cycle, the second half of the year is poised for heightened activity in digital health and health investment. There will be a market division between winners and losers, with successful companies continuing to grow, while struggling ones face a lack of investor confidence. The correction in 2023 is evident in the realm of digital health and health tech investments, with valuations undergoing adjustments and the time required to build healthcare companies becoming longer. The focus is predicted to shift from early-stage to later-stage investments, as private equity and venture capital seek tangible returns in a market that has experienced a 40 to 50% decline in investment over the last two years. The prospect of IPOs, particularly from well-established companies like Doctolib and Kaia Health, which have garnered substantial funding over the past decade, looms on the horizon. Valuations now are projected to pick up, paving the way for increased consolidation and roll-up deals in the market. A trend is emerging here, where investors weigh options to either inject more capital, divest, or merge with larger entities, driven by the notion of "stronger together". Within sub-sectors, digital therapeutics and software with SAS-driven models will remain resilient, while digital health apps may experience a relative downturn. Recognising the growing significance of integrators - I call them "bridges and tunnels" - in the healthcare industry's middle layer points to a shift in focus towards the critical infrastructure that underpins the sector. Last, there will be an uptick in evidence requirements, the integration of data and infrastructure in healthcare is deemed increasingly vital. The involvement of big tech in healthcare is expected to increase, and the evolving role of generative AI, transitioning from early adoption to mass market acceptance, raises questions about its potential applications in healthcare in the coming year. About HealthInvestor HealthInvestor UK is the leading news source and website for investors, operators, lenders and advisors focused on the UK health and social care sector. Our team of experienced journalists provide readers with the latest market news and analysis through our website and monthly magazine. Our offering for subscribers includes: • News covering all the month’s important business deals and policy developments • Analysis offering a critical look at key events • Features that offer in-depth examinations of the industry’s hot topics, such as social care policy and new sources of investment • Profiles of the sector’s major players • A comprehensive summary of healthcare company results • Round-up of executive appointments • Daily news updates • A database of signed healthcare deals • An archive of magazine articles • The latest executive moves and new job openings • A listing of upcoming conferences and events Plus • A weekly email alert offering a summary of the week’s news straight to your inbox • Regular supplements on topics such as healthcare law, finance and property www.healthinvestorintel.com – a website containing the latest business intelligence, thought leadership and research for the UK independent health and social care sector •Discounts on selected HealthInvestor UK events http://www.healthinvestor.co.uk

Health Tech founder and M&A Advisor Lloyd Price believes virtual care can bring a sweep of benefits, but cautions that it will still need to find a way through barriers around access and affordability for patients, the security of patient data and the licensing of healthcare providers to practice across geographical and care boundaries. Original Source: https://www.pmlive.com/pme#/reader/50530/247673 Author: Danny Buckland, a journalist specialising in the healthcare industry Virtual Care – negotiating barriers to adoption offers glimpses of an exciting future The predictive genius and jeopardy of futuristic machine intelligence that underpin most sci-fi films are scripting a way forward for stressed healthcare systems and rampaging R&D costs. It may be a good while before we reach pre-cognitive techniques to ward off disease and accidents, but virtual reality is forging radical recalibrations of everything from drug discovery to bedside care in both the home and the hospital setting. In the 2002 Hollywood blockbuster film Minority Report, Tom Cruise’s character merely had to nod or concentrate his gaze to unlock screens of data to help him navigate a danger-laden futuristic life. That type of delivery is yet to be developed, but the data that drives it is being generated in terabytes every second of the day. Virtual care – a digital-driven spectrum from wearables to virtual hospital wards – is viewed by many as a vital weapon in meeting the global challenges of ageing populations living with multiple comorbidities that are straining financial and human resources. Its ability to synchronise monitoring of patients at home or at local clinics and to provide diagnostic, treatment and clinical trials intelligence can be transformative. The WHO and the India G20 presidency emphasised its importance by launching ‘The Global Initiative of Digital Health’ (GIDH) in August, proclaiming: “Digital health is a proven accelerator to advance health outcomes and achieve Universal Health Coverage and health-related Sustainable Development Goals.” “Technology-enabled virtual care solutions have become pivotal at the intersection of healthcare and life sciences to support remote patient monitoring and engagement, driving a transformative shift toward new, patient-centric models of healthcare delivery and clinical research,” observed Nino Giguashvili, research manager for technology analysts and advisors at IDC Health Insights. “Following the period of exponential surge experienced throughout the COVID-19 pandemic, virtual care has now reached a critical juncture that will shape its future trajectory.” Virtual wards are springing up across the cloud, with the NHS in England targeting a capacity for 10,000 beds by the end of the year. It will have immediate potential to reduce the backlog of almost eight million operations, but it is also a template for healthcare systems struggling to cope with increased pressures, diminishing budgets and dawdling processes. Transforming healthcare A report from the London School of Economics, The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health, published in 2021, forecast that the pharmaceutical industry would be a core player in all aspects from population health management to preventive and therapeutic care. It stated: ‘By 2025, global spend on digital health is predicted to reach €1tn and digital products and services will grow to a market share of 12% (Choueiri et al., 2020), leaving little doubt that virtual health and digital platforms will transform healthcare in the coming years.’ The report cited staff shortages, patient demand, advancing technologies – from wearables to AI – and the reshaping of health delivery during the pandemic as key drivers of the sector surge and viewed the pharmaceutical industry as having a critical role to play in further advances, due to its knowledge of health conditions, patient behaviour, its application of data and experience researching and bringing products to market. European healthcare systems are wrestling with the mechanisms of adopting virtual care capabilities and collaborating with industry and digital innovators to realise improved patient outcomes and better connected, cost-effective care. Lessons are being learned daily. “Virtual care has a significant role to play in the future sustainability of healthcare systems around the world,” observes Kate Kelly, Managing Director UK & Ireland, Inizio Engage, a global strategic, commercial and creative engagement agency specialising in healthcare. “It offers ease of access to services to patients, clinicians and HCPs, enabling improved diagnostics and enhanced support of chronic conditions. “It also leads to the prevention of hospital admissions through earlier detection of conditions and allows more patients to be treated in community settings rather than hospitals. Virtual care can also reach individuals in remote locations, where their attendance might generally be poor due to travel and or mobility needs. “Virtual care also generates a wealth of patient data captured in real-time reporting across patient populations, health information, treatment responses, lifestyle patterns and medication adherence. All of this generates better understanding of patient responses to treatment, adherence and overall patterns of behaviour, and empowers capabilities to review trends, patient cohorts and treatments and therefore structure programmes and clinical trials in a more targeted and effective way.” ‘Virtual care is viewed by many as a vital weapon in meeting the global challenges of ageing populations living with multiple comorbidities’The ability to understand patient populations to synchronise R&D and therapy delivery is like gold dust for healthcare systems, industry and, above all, patients. But it is still a frontier opportunity riven with regulatory considerations and safety concerns. The digital tools that power virtual care need assessment and approvals to satisfy clinical safety, data protection, cyber security and regulatory requirements. Further challenges exist in how virtual care is integrated into existing frameworks, how patients access it and how to ensure it can develop without bureaucratic delays. Boosting quality of life “It is also vital to consider the patients who will be using digital tools,” comments Kate.  “They need to be fully informed and have trust in the digital tool they are using to ensure full compliance so that invaluable data can be obtained and utilised effectively. The patient experience needs to be positive to ensure engagement and adherence. “Driving forward virtual care means more care can be delivered at home with measurable improvements to their quality of life and independence. The savings to healthcare systems from reduced hospital admissions and streamlined services will have a big impact on costs and treatment affordability as well as reducing current backlogs. “Virtual care gives us the opportunity to deliver care in multiple different ways and changes the format of care delivery as we move forwards. This was accelerated with the pandemic and the urgent need to do things differently.” The rapid rate of change places a heavy emphasis on agile process and sharply-tuned data, and Inizio Engage has created a FutureFraming capability to future-proof its processes and skills to respond to new opportunities and demand surges. The exhilarating pace of change is evidenced at Cera, a digital-first home healthcare enterprise that has seen the patient visits that drive its processes increase from 120,000 in 2019 to 18 million in 2023. It has established the largest home healthcare data set in Europe (150+ billion data points) through care plans, care visits and sensor technology, which it uses to leverage machine learning and artificial intelligence to fuel continuous improvements in patient health outcomes. Cera, which is one of the fastest growing sector companies in Europe, has been able to reduce hospital admissions by 52% across the care it delivers to 20 million people and it is springboarding more growth by augmenting its existing systems with AI and ChatGPT technology. Trust and reliability issues “Virtual patient care is increasingly recognised as a critical component in enhancing healthcare delivery and patient outcomes,” says Luigi De Curtis, VP of Growth at Cera, which operates in the UK and Germany. “It helps address the gap in care and clinical staff and is much more cost-effective than treatment in hospital and, most importantly, it also drives better patient outcomes overall, because virtual care allows for real-time health data collection that enables better informed and timely medical decisions. “Our rapid expansion reflects the evolving needs of an ageing population and the challenges of the health system, particularly in relation to cost and capacity pressures. This growth is not just a measure of our impact, but also an indicator of the trust and reliability that patients and healthcare providers place in digital health solutions like Cera. “Digital technology is pivotal in building sustainable healthcare systems, enhancing efficiency across various aspects of healthcare from diagnostics to tailored therapies.” The attraction of virtual care is clear with major organisations collaborating with digital health companies at a higher rate and with bigger deals. In November, Merck KGaA partnered with Huma Therapeutics to develop digital solutions to help cancer patients better understand and manage their conditions and treatment protocols to encourage adherence. Roche’s navify portfolio of digital solutions aims to maximise healthcare insights and performance through integrated data that, it states, ‘connects the healthcare community, delivering clinical, operational and financial value, accelerating innovation and unlocking opportunities for better care’. It was recently deployed at the Hospital del Mar, Barcelona, to help its tumour board to standardise and improve process to enhance cancer treatment. A GlobalData market report on virtual care observed: ‘Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios, but are also making strategic investments in virtual care. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of virtual care in the pharmaceutical industry.’ Accelerating drug development Health Tech founder and M&A Advisor Lloyd Price believes virtual care can bring a sweep of benefits, but cautions that it will still need to find a way through barriers around access and affordability for patients, the security of patient data and the licensing of healthcare providers to practice across geographical and care boundaries. “Despite these challenges, pharma partnering with digital health companies will continue to grow, because they offer access to new technologies, such as AI and machine learning, that can help accelerate drug development and innovation,” he observes. “Digital health companies can help identify new drug targets, design clinical trials and analyse data more effectively. “Digital health solutions can also help pharma companies to improve patient engagement and adherence to treatment plans. For example, wearable devices can track patient activity and medication adherence, and digital platforms can provide patients with personalised education and support. “The collaborations also promise new revenue streams through developing digital therapeutics, which are software-based treatments for a variety of medical conditions.” Huge levels of activity and transformation are expected over the next few years, with industry becoming even more entwined with digital. The sci-fi leaps of fantasy in Minority Report may never all come true but, as the film reaches its 25th anniversary, healthcare will have a new reality. Pharmaceutical Market Europe (PME) PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night. From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered. PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.

In a new series of Digital Health Intelligence Market Analysis, HealthTech Founder and M&A Advisor Lloyd Price examines a range of high potential market segments in the UK, including: 1. Virtual Care – From Hype to Reality 2. Patient Engagement Platforms – Rebuilding Trust in the NHS 3. Population Health – from Reactive Care to Proactive Prevention 4. Digital Therapeutics – looking forward to a year of growth Digital Health Intelligence Market Analysis - from identifying high value market segments to sales prospecting, Intelligence supports multiple teams with essential insights and reliable, granular-level data on NHS acute and mental health trusts, central bodies, STPs, ICSs and commissioning organisations. Digital Health Intelligence is the 'Trusted Authority on Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT 1. DHI Market Analysis: Virtual Care – From Hype to Reality In the first of a new series of analyses for Digital Health Intelligence subscribers, Lloyd Price examines the virtual care market. Virtual care holds potential in healthcare delivery, blending innovation with tradition. However, beneath the surface lies complexity. NHS frontline staff, navigating post-COVID challenges, perceive virtual wards as additional digital tasks, amid staffing shortages and mounting hurdles. 2. DHI Market Analysis: Patient Engagement Platforms – Rebuilding Trust in the NHS Patient engagement platforms are gaining momentum with NHS England’s backing. They’re central to the ‘Digital Front Door’ strategy, focusing on patient-facing services, enhancing secondary care, and reducing the strain on frontline services. These platforms address the pandemic-induced disconnect between patients and the NHS. 3. DHI Market Analysis: Population Health – from Reactive Care to Proactive Prevention This report offers a comprehensive overview of the evolving landscape of population health management and the challenges and opportunities it presents to the NHS. It underscores the importance of proactive approaches to healthcare and the critical role that data and technology will play in shaping the future of healthcare in the UK. 4. DHI Market Analysis: Digital Therapeutics – looking forward to a year of growth The Digital Health Intelligence (DHI) Market Analysis on Digital Therapeutics highlights the transformative impact of evidence-based interventions delivered through devices. In the past year, there has been a significant surge in the adoption of digital therapeutics, especially within the NHS, addressing various healthcare challenges. Digital Health Intelligence is the 'Trusted Authority on Health IT, HealthTech and Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT Digital Health Intelligence: Digital Health provides independent business, policy and technology news, research and events focused on developments in health IT in the NHS and UK health. Our coverage is focused, original and authoritative. Over 20,000 readers subscribe to Digital Health’s newsletters. Digital Health News provides daily news and analysis on the UK health IT sector, spanning NHS IT infrastructure, enterprise and clinical systems such as EPR (electronic patient records) to emerging and disruptive technologies, including AI, apps and wearables. Digital Health Intelligence is our market intelligence data business providing the most detailed database available on the current systems, technology and infrastructure installed at every NHS trust in the UK, together with future purchasing intentions and market trends analysis. The subscription-based service enables suppliers to understand and target market opportunities. Digital Health Intelligence is the 'Trusted Authority on Health IT, HealthTech and Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT

Exec Summary: Rollup strategies are expected to play a significant role in shaping the HealthTech landscape in 2024. This approach involves acquiring multiple smaller companies within a specific sector and consolidating them into a larger, more unified entity. This strategy offers several potential benefits, including: Increased Scale and Efficiency: By combining resources and expertise, rollups can achieve greater economies of scale, leading to improved operational efficiency and reduced costs. Enhanced Market Reach and Brand Recognition: Larger, more established rollups gain broader market reach and recognition, making them more attractive to customers, partners, and investors. Diversified Product Offerings and Revenue Streams: Rollups can expand their product portfolio and revenue streams by incorporating the offerings of acquired companies, reducing their reliance on a single product or service. Accelerated Innovation and Growth: Rollups can leverage the collective knowledge and expertise of acquired companies to accelerate innovation and drive faster growth. In the context of HealthTech, rollup strategies are particularly appealing due to the industry's fragmented nature, with numerous small, niche players operating in various subsectors. By consolidating these companies, rollups can create comprehensive platforms that address a wider range of healthcare needs, catering to a broader customer base. Here are some specific examples of how rollup strategies are likely to impact HealthTech in 2024: Virtual Care Platforms: Rollups can aggregate telemedicine, remote patient monitoring, and virtual behavioral health companies to establish comprehensive virtual care platforms that provide seamless and coordinated care across various healthcare settings. Mental Health and Wellness Platforms: Rollups can combine companies offering therapy, counseling, mindfulness apps, and digital therapeutics to create holistic mental health and wellness platforms that address the growing demand for mental healthcare. Digital Health Data Platforms: Rollups can integrate companies specializing in electronic health records (EHRs), patient data analytics, and clinical decision support tools to develop integrated data platforms that improve patient care and outcomes. Precision Medicine Platforms: Rollups can bring together companies focused on genetic testing, personalised medicine, and data analytics to create precision medicine platforms that tailor treatment plans to individual patients' genetic and molecular profiles. As rollup strategies gain traction in HealthTech, we can expect to see the emergence of dominant players in various subsectors. These rollups will reshape the competitive landscape, driving innovation, improving patient care, and influencing the future of healthcare delivery. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk What is a HealthTech platform? A healthtech platform is a software application or website that uses technology to deliver healthcare services or products. These platforms can be used for a wide range of purposes, including: Connecting patients with providers: Healthtech platforms can make it easier for patients to find and connect with healthcare providers, such as doctors, nurses, and therapists. This can be done through online directories, scheduling tools, and telemedicine services. Providing access to health information: Healthtech platforms can provide patients with access to a wealth of health information, including medical records, educational resources, and personalized health assessments. This can help patients make informed decisions about their care. Managing chronic conditions: Healthtech platforms can help patients manage chronic conditions, such as diabetes or heart disease. This can be done through self-monitoring tools, medication reminders, and data sharing with providers. Supporting clinical decision-making: Healthtech platforms can provide clinicians with tools and data to support their decision-making. This can include electronic health records, clinical decision support systems, and data analytics tools. Healthtech platforms are a rapidly growing area of healthcare, and they have the potential to revolutionize the way that healthcare is delivered. By leveraging technology, healthtech platforms can make healthcare more accessible, convenient, and effective for everyone. Here are some examples of healthtech platforms: Zocdoc: Zocdoc is an online platform that allows patients to find and book appointments with healthcare providers. WebMD: WebMD is a website that provides patients with access to health information, including medical news, articles, and tools. 23andMe: 23andMe is a genetic testing company that provides patients with information about their ancestry and health risks. Fitbit: Fitbit is a wearable device that tracks patients' activity, heart rate, and sleep. Startups are expected to play a key role in healthtech rollup strategies in 2024 Young, innovative companies often possess cutting-edge technologies and solutions that can be highly valuable to rollup companies. As rollups seek to consolidate their market positions and expand their offerings, they will increasingly turn to startups for these valuable assets. Here are some of the specific ways in which startups are likely to contribute to healthtech rollup strategies in 2024: Technology Acquisition: Rollup companies may acquire startups to gain access to their proprietary technologies. These technologies could be used to develop new products, services, or platforms, or to enhance the capabilities of existing offerings. Talent Acquisition: Startups often attract and retain top talent in the healthtech industry. Rollup companies may acquire startups to gain access to this talent pool and bolster their own innovation and development capabilities. Market Entry: Startups can provide rollup companies with a foothold in new markets or customer segments. By acquiring startups, rollups can quickly expand their reach and broaden their customer base. Proof of Concept: Startups can provide rollup companies with a proof of concept for new technologies or business models. Once a startup has demonstrated the viability of its approach, a rollup company can acquire it and scale the solution more broadly. Pipeline of Innovation: Startups can serve as a pipeline of innovation for rollup companies. By maintaining relationships with startups, rollups can gain early access to new technologies and trends, allowing them to stay ahead of the competition. Overall, startups are expected to play a critical role in the healthtech rollup landscape in 2024. Their innovative technologies, talented teams, and access to new markets make them highly attractive partners for rollup companies seeking to expand and grow. As the rollup trend continues to gain momentum, startups are well-positioned to capitalize on these opportunities and make significant contributions to the future of healthtech. Private Equity rollup strategies in HealthTech to focus on the 'Forgotten MidTier' Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity firms that are looking for companies with the potential for double-digit growth. The healthcare technology (healthtech) industry is vast and growing, with a wide range of companies at different stages of development. Private equity firms have traditionally focused on investing in the largest and most well-known healthtech companies, such as those that have achieved unicorn status. However, there is a growing opportunity for private equity firms to invest in the midtier of the healthtech landscape. Some of the benefits of investing in midtier healthtech companies include: Lower risk: Midtier healthtech companies are less likely to fail than the largest healthtech companies. This is because they have already demonstrated a proof of concept and have won flagship customers. Double-digit growth: Midtier healthtech companies have the potential for double-digit growth. This is because they are still in the early stages of their development and have a lot of room to grow. Expertise: Private equity firms can bring their expertise to help midtier healthtech companies scale and grow. This can include providing access to capital, strategic guidance, and operational support. Some of the challenges of investing in midtier healthtech companies include: Competition: The midtier healthtech landscape is becoming increasingly competitive. This is because there are more and more companies vying for a share of the market. Regulation: The healthcare industry is highly regulated. This can make it difficult for midtier healthtech companies to navigate the regulatory landscape. Exit: There are fewer potential buyers for midtier healthtech companies than for larger companies. This can make it difficult for private equity firms to exit their investments. Overall, there is a growing opportunity for private equity firms to invest in the midtier of the healthtech landscape. These companies offer the potential for double-digit growth with a lower risk profile than the largest healthtech companies. However, there are also some challenges that private equity firms need to be aware of, such as competition and regulation. Blockbuster healthtech rollup strategies expected to make a big impact in 2024 Here are some of the blockbuster healthtech rollup strategies that are expected to make a big impact in 2024: 1. Mental health: Mental health is one of the most promising areas for healthtech rollups in 2024. The market for mental health services is expected to reach $200 billion by 2025, and there is a growing demand for digital solutions that can provide affordable and accessible care. Rollup companies can acquire startups that are developing innovative mental health apps, teletherapy platforms, and other digital tools to create a comprehensive mental health platform. 2. Telehealth: Telehealth is another area that is ripe for rollup activity in 2024. The telehealth market is expected to reach $285 billion by 2026, and there is a growing demand for virtual care solutions that can provide patients with convenient and affordable access to medical services. Rollup companies can acquire startups that are developing telehealth platforms for specific specialties, such as dermatology, cardiology, and oncology, to create a comprehensive telehealth platform. 3. Wearables: The wearables market is expected to reach $80 billion by 2025, and there is a growing demand for devices that can track health data and provide insights into users' health and fitness. Rollup companies can acquire startups that are developing innovative wearables with new sensors and features, such as continuous glucose monitoring and ECG tracking, to create a comprehensive wearables platform. 4. Artificial intelligence (AI): AI is being used in a variety of ways to transform healthcare, and rollup companies are well-positioned to capitalize on this trend. Rollup companies can acquire startups that are developing AI-powered solutions for drug discovery, clinical decision support, and patient monitoring to create a comprehensive AI-powered healthcare platform. 5. Data analytics: Data analytics is essential for understanding and improving healthcare. Rollup companies can acquire startups that are developing data analytics platforms to help healthcare providers collect, analyze, and use healthcare data to improve patient care and outcomes. These are just a few of the blockbuster healthtech rollup strategies that are expected to make a big impact in 2024. As technology continues to advance, we can expect to see even more innovative and transformative healthtech rollups emerge in the years to come. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Executive Summary: The average multiples for digital therapeutics (DTx) M&A deals in 2023 are as follows: Enterprise value (EV) to sales: 5.6x EV to EBITDA: 12.5x These multiples are down from the levels seen in 2022, but they are still higher than the average EV to sales multiple for all industries. The decline in multiples is likely due to a number of factors, including: The increasing number of DTx companies entering the market The increasing competition from traditional pharmaceutical companies The regulatory uncertainty surrounding DTx products Despite these challenges, the DTx market is still expected to grow significantly in the coming years. This is due to a number of factors, including: The increasing prevalence of chronic diseases The rising cost of healthcare The increasing demand for patient-centered care As a result, DTx companies are still expected to be attractive targets for M&A deals. However, investors are likely to be more cautious about their valuations, and they will be more likely to pay a premium for companies with strong growth prospects, a differentiated product or service offering, and a large addressable market. Here are some additional insights into DTx M&A deals in 2023: The most active acquirers in the DTx M&A market are pharmaceutical companies, followed by technology companies. The most active subsectors for DTx M&A deals are mental health, oncology, and diabetes. The average deal size for DTx M&A deals is increasing. Overall, the DTx M&A market is expected to remain active in 2023. However, investors are likely to be more cautious about their valuations, and they will be more likely to pay a premium for companies with strong growth prospects, a differentiated product or service offering, and a large addressable market. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk Digital Therapeutics (DTx): Digital therapeutics (DTx) are clinically validated software-based therapeutic interventions that use digital and technological solutions to prevent, manage, or treat a medical disorder or disease. They function as prescription digital medicines that are regulated as medical devices. DTx products are delivered directly to patients through their smartphones, tablets, or other personal devices. Key Characteristics of DTx: Evidence-based: DTx interventions are grounded in scientific evidence and clinical research, demonstrating efficacy and safety in treating specific medical conditions. Software-driven: DTx products rely on software algorithms and digital technologies to deliver therapeutic interventions, such as behavioral modification, cognitive training, or symptom management tools. Patient-centered: DTx empowers patients to actively engage in their own care, providing personalized interventions, self-management tools, and real-time feedback. Clinically evaluated: DTx products undergo rigorous clinical trials to ensure their safety and effectiveness, similar to traditional pharmaceuticals. Regulated as medical devices: DTx products are regulated by relevant regulatory bodies, such as the FDA in the United States, to ensure patient safety and compliance with quality standards. Examples of DTx Applications: Mental health: DTx programs address conditions like anxiety, depression, insomnia, and post-traumatic stress disorder (PTSD) through behavioral therapy, cognitive training, and mindfulness techniques. Cardiovascular health: DTx interventions can help manage hypertension, heart failure, and other cardiovascular conditions by providing personalized monitoring, lifestyle coaching, and medication adherence support. Diabetes management: DTx products can assist in blood glucose control, insulin therapy management, and lifestyle modification for diabetes patients. Chronic pain management: DTx programs can help manage chronic pain conditions by providing cognitive-behavioral therapy, relaxation techniques, and biofeedback training. Musculoskeletal disorders: DTx interventions can help manage conditions like arthritis, low back pain, and chronic fatigue syndrome through exercise guidance, pain management strategies, and self-monitoring tools. DTx represents a promising new era in healthcare, offering innovative and accessible therapeutic solutions for a wide range of medical conditions. Key Drivers of DTx M&A Deals in 2023: The digital therapeutics (DTx) M&A market is rapidly growing, driven by a number of key factors: Rising prevalence of chronic diseases: The increasing prevalence of chronic diseases such as diabetes, obesity, and hypertension is a major driver of the DTx market. These conditions often require long-term management, and DTx offers a convenient and cost-effective way to provide care. Growing adoption of digital health technologies: The increasing adoption of digital health technologies, such as smartphones, wearable devices, and telehealth platforms, is creating a more favorable environment for DTx solutions. These technologies allow for the delivery of personalized and real-time care, which is essential for many chronic conditions. Positive regulatory landscape: The regulatory landscape for DTx is becoming more favorable, with increasing recognition of the potential benefits of these products. This is encouraging more investment and development in DTx, and it is also making it easier for companies to bring their products to market. Emerging reimbursement models: There is a growing movement towards value-based care, which is a healthcare delivery model that emphasizes the quality and effectiveness of care over the quantity of services provided. DTx products are often well-suited to value-based care models, as they can be shown to improve patient outcomes and reduce healthcare costs. Strategic acquisitions for market expansion: Pharmaceutical companies are increasingly acquiring DTx companies as a way to expand their product portfolios and gain access to new markets. DTx products can be complementary to traditional pharmaceuticals, and they can also help pharmaceutical companies improve their patient engagement and adherence. Consolidation of the DTx market: As the DTx market matures, there is a trend towards consolidation, with larger companies acquiring smaller companies to gain market share and expand their product offerings. This consolidation is helping to accelerate the development and adoption of DTx solutions. Increasing investor interest: Venture capitalists and private equity firms are increasingly investing in DTx companies, as they see the potential for these products to revolutionize the way healthcare is delivered. This influx of capital is helping to fuel the growth of the DTx market. COVID-19 pandemic: The COVID-19 pandemic has accelerated the adoption of digital health technologies, and this has also had a positive impact on the DTx market. DTx products can be used to provide remote care, which is essential during a pandemic when in-person visits are limited. These factors are all contributing to the growth of the DTx M&A market, and we can expect to see continued consolidation and innovation in this space in the years to come. Future of Digital Therapeutics (DTx) M&A: The future of digital therapeutics (DTx) M&A is bright, with continued growth expected in the coming years. Several factors are driving this trend, including: Growing demand for DTx: The demand for DTx is increasing as patients, providers, and payers recognize the potential of these products to improve health outcomes and reduce healthcare costs. Expanding DTx applications: The range of DTx applications is expanding to address a wider range of medical conditions, including mental health, cardiovascular health, diabetes, pain management, and musculoskeletal disorders. Maturing DTx market: The DTx market is maturing, with more companies developing and commercializing their products. This is leading to increased competition and innovation, which is benefiting patients. Favorable regulatory environment: The regulatory environment for DTx is becoming more favorable, with increasing recognition of the safety and efficacy of these products. This is making it easier for companies to bring their products to market. Emerging reimbursement models: New reimbursement models are emerging that are more supportive of DTx products. This is making it easier for patients to access these products and for payers to cover them. Strategic acquisitions: Pharmaceutical companies and technology companies are increasingly acquiring DTx companies to gain access to new markets and technologies. This is consolidating the market and accelerating innovation. As a result of these factors, we can expect to see continued consolidation and innovation in the DTx M&A market in the years to come. Here are some specific trends to watch for: Increased acquisitions by pharmaceutical companies: Pharmaceutical companies are increasingly recognizing the potential of DTx to complement their traditional drug therapies. As a result, we can expect to see more acquisitions of DTx companies by pharmaceutical companies in the coming years. Expansion into new markets: DTx companies are expanding into new markets, such as emerging markets and international markets. This is creating new opportunities for M&A activity. Vertical integration: We can expect to see more vertical integration in the DTx market, with companies acquiring partners that provide complementary technologies or services. This will help companies to provide more comprehensive solutions to patients. Platform acquisitions: We can also expect to see more acquisitions of DTx platforms, which are software platforms that allow developers to create and deploy DTx products. This will help to accelerate the development and adoption of new DTx products. Overall, the future of DTx M&A is bright. The increasing demand for DTx, the expanding range of applications, and the maturing regulatory environment are all driving consolidation and innovation in this space. As a result, we can expect to see significant growth in the DTx M&A market in the years to come. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Exec Summary: Sam Altman is a highly respected entrepreneur and technologist with a deep understanding of artificial intelligence (AI) and its potential to transform healthcare. His expertise in AI, combined with his experience in building successful businesses, could bring significant benefits to Microsoft's healthcare initiatives. Here are some specific areas where Sam Altman's expertise could be particularly valuable: AI Strategy and Development: Altman's experience leading OpenAI, a leading AI research lab, provides him with a deep understanding of the current landscape of AI technologies and their potential applications in healthcare. He can guide Microsoft in identifying the most promising AI technologies to invest in and develop, ensuring that the company is at the forefront of AI innovation in healthcare. AI Talent Acquisition and Management: Altman has a proven track record of attracting and retaining top talent in the tech industry. He can help Microsoft build a world-class team of AI engineers, researchers, and clinicians to develop and deploy AI solutions for healthcare. AI Ethics and Governance: As a co-founder of OpenAI, Altman has been deeply involved in discussions about the ethical use of AI. He can help Microsoft establish clear ethical guidelines and governance frameworks for the development and deployment of AI in healthcare, ensuring that AI is used responsibly and benefits patients. AI Business Development and Partnerships: Altman's experience in building successful businesses will be invaluable in translating AI technologies into viable healthcare solutions. He can help Microsoft identify and partner with healthcare organizations, pharmaceutical companies, and other stakeholders to develop and commercialize AI-powered healthcare products and services. AI Advocacy and Public Engagement: Altman is a strong advocate for the use of AI to address global challenges, including healthcare. He can help raise awareness of Microsoft's AI initiatives in healthcare and build public support for the responsible development and deployment of AI in the healthcare sector. Sam Altman's arrival at Microsoft could significantly accelerate the company's efforts to utilize AI to improve healthcare outcomes. His expertise, experience, and leadership will be invaluable in guiding Microsoft to become a leader in AI-powered healthcare solutions. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk Microsoft's plans for AI in Healthcare in the next few years Microsoft has several key areas of focus for its AI initiatives in healthcare over the next two years: Improving patient engagement and experience: Microsoft is developing AI-powered tools to help healthcare providers communicate more effectively with patients, provide more personalized care, and improve patient outcomes. For example, the company is developing chatbots that can answer patients' questions, schedule appointments, and provide reminders for follow-up care. Enhancing clinical decision-making: Microsoft is using AI to develop tools that can help clinicians make better decisions about patient care. For example, the company is developing AI algorithms that can analyze medical images to detect early signs of disease, and AI-powered tools that can help clinicians identify patients at risk of adverse events. Streamlining administrative tasks: Microsoft is using AI to automate administrative tasks, such as billing and coding, so that clinicians can focus on patient care. For example, the company is developing AI-powered tools that can automatically extract data from electronic health records and code it for reimbursement purposes. Accelerating research and development: Microsoft is partnering with healthcare organizations and researchers to accelerate the development of new AI-powered healthcare solutions. For example, the company is supporting the development of AI-powered tools for early diagnosis and treatment of cancer. In addition to these specific initiatives, Microsoft is also working to make its AI tools more accessible to healthcare organizations of all sizes. The company is offering a variety of cloud-based AI services that can be easily integrated with existing IT systems, and it is providing training and support to help healthcare providers adopt and use AI effectively. Overall, Microsoft is committed to using AI to improve the quality, efficiency, and affordability of healthcare. The company's investments in AI are having a significant impact on the healthcare industry, and they are expected to continue to do so in the years to come. Here are some specific examples of Microsoft's AI initiatives in healthcare: Microsoft Azure Machine Learning for Healthcare: This cloud-based platform provides healthcare organizations with a suite of AI tools that can be used to analyze medical images, identify patients at risk of adverse events, and develop personalized care plans. Microsoft Healthcare Bot: This chatbot can answer patients' questions, schedule appointments, and provide reminders for follow-up care. Microsoft Azure Cognitive Services for Healthcare: This suite of AI APIs can be used to extract data from medical texts, translate medical documents, and analyze patient sentiment. Microsoft AI for Health: This research initiative is focused on developing new AI-powered healthcare solutions, such as AI algorithms for early diagnosis and treatment of cancer. These are just a few examples of Microsoft's many AI initiatives in healthcare. The company is constantly developing new AI tools and solutions, and it is committed to using AI to improve the lives of patients around the world. Final Thoughts: Given Sam Altman's expertise in artificial intelligence (AI), his initial project at Microsoft could potentially focus on integrating AI into various aspects of healthcare. Here are a few potential areas where he could make a significant impact: Developing AI-powered tools for patient diagnosis and treatment: Altman could lead a team of AI researchers and clinicians to develop AI algorithms that can analyze medical images, electronic health records, and other data to identify patterns and make predictions about patient diagnoses, treatment options, and potential risks. These AI tools could assist healthcare providers in making more informed and timely decisions, potentially improving patient outcomes. Creating AI-driven chatbots and virtual assistants for patient engagement: Altman could oversee the development of AI-powered chatbots and virtual assistants that can interact with patients, answer their questions, provide personalized healthcare information, and schedule appointments. These AI companions could enhance patient engagement, improve access to care, and reduce administrative burdens for healthcare providers. Utilizing AI to optimize healthcare operations and resource allocation: Altman could spearhead the application of AI to optimize hospital operations, patient flow, and resource allocation. AI algorithms could analyze patient data, predict patient needs, and suggest efficient scheduling, staffing, and resource utilization strategies to improve healthcare delivery and reduce costs. Developing AI-powered drug discovery and development tools: Altman could lead a team of AI experts and scientists to develop AI algorithms that can analyze vast amounts of biological data to identify potential drug targets, predict drug efficacy and safety, and accelerate the drug discovery process. These AI tools could revolutionize the pharmaceutical industry and lead to the development of more effective and safer treatments for various diseases. Establishing a Microsoft AI for Healthcare research institute: Altman could establish a dedicated research institute within Microsoft to focus on developing and applying AI to address critical healthcare challenges. This institute could bring together researchers, clinicians, and AI experts from various disciplines to collaborate on innovative AI-powered healthcare solutions. These are just a few potential areas where Sam Altman could make a significant impact at Microsoft. His expertise in AI, combined with his experience in building successful businesses and his passion for leveraging technology to solve global challenges, makes him well-positioned to lead Microsoft's AI initiatives in healthcare and transform the future of healthcare delivery. It will be exciting to see how Sam Altman's expertise and leadership shape the future of AI in healthcare at Microsoft. His contributions could have a profound impact on improving patient outcomes, enhancing healthcare delivery, and transforming the healthcare industry as a whole. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Europe Predictions for the European HealthTech landscape in 2024: Increased investment in mental health: The COVID-19 pandemic has had a significant impact on mental health, and there is a growing recognition of the need for better mental health care. This is likely to lead to increased investment in mental health tech startups in Europe in 2024. More focus on digital therapeutics: Digital therapeutics are software-based interventions that are designed to prevent, manage, or treat diseases and disorders. They are becoming increasingly popular as they can be more cost-effective and convenient than traditional treatments. In 2024, we can expect to see more European healthtech startups developing and launching digital therapeutics products. Greater adoption of artificial intelligence (AI): AI is already being used in healthcare in a variety of ways, such as for diagnosing diseases, developing new treatments, and improving the efficiency of healthcare systems. In 2024, we can expect to see even greater adoption of AI in European healthcare, including in the healthtech sector. More collaboration between healthtech startups and traditional healthcare providers: Healthtech startups are increasingly collaborating with traditional healthcare providers to develop and deliver new products and services. This trend is likely to continue in 2024, as healthcare providers recognize the need to adopt new technologies to improve the quality and efficiency of care. Here are some specific examples of HealthTech trends that we may see in Europe in 2024: The rise of mental health platforms: Mental health platforms provide users with access to a variety of resources, such as online therapy, self-help tools, and peer support communities. These platforms are becoming increasingly popular, and we can expect to see more European healthtech startups developing and launching mental health platforms in 2024. The development of new digital therapeutics products: Digital therapeutics products are still in their early stages of development, but they have the potential to revolutionize the way we treat and manage diseases. In 2024, we can expect to see more European healthtech startups developing and launching new digital therapeutics products for a variety of conditions. The use of AI to improve the efficiency of healthcare systems: AI is already being used to improve the efficiency of healthcare systems in a variety of ways, such as by automating tasks and providing clinicians with insights into patient data. In 2024, we can expect to see even greater adoption of AI in healthcare systems across Europe. The development of new AI-powered diagnostic tools: AI-powered diagnostic tools can help clinicians to diagnose diseases more accurately and efficiently. In 2024, we can expect to see more European healthtech startups developing and launching new AI-powered diagnostic tools for a variety of diseases. The growth of telemedicine: Telemedicine allows patients to receive healthcare services remotely, via video conferencing or other digital channels. Telemedicine became increasingly popular during the COVID-19 pandemic, and this trend is likely to continue in 2024. Overall, the European HealthTech landscape is expected to grow and evolve rapidly in 2024. We can expect to see more investment in the sector, the development of new and innovative healthtech products and services, and the increased adoption of healthtech by traditional healthcare providers. Middle East Predictions for the Middle East HealthTech landscape in 2024: Increased investment in Middle Eastern healthtech startups: The Middle East healthtech sector is attracting increasing investment from both local and international investors. This is likely to continue in 2024, as investors recognize the potential of Middle Eastern healthtech startups to address the region's healthcare challenges. More focus on preventive healthcare: There is a growing awareness of the importance of preventive healthcare in the Middle East. This is leading to increased investment in healthtech solutions that promote preventive care, such as wearable devices, fitness tracking apps, and telemedicine platforms. Greater adoption of artificial intelligence (AI) in Middle Eastern healthcare: AI is already being used in healthcare in the Middle East in a variety of ways, such as for diagnosing diseases, developing new treatments, and improving the efficiency of healthcare systems. In 2024, we can expect to see even greater adoption of AI in Middle Eastern healthcare, including in the healthtech sector. More collaboration between Middle Eastern healthtech startups and traditional healthcare providers: Middle Eastern healthtech startups are increasingly collaborating with traditional healthcare providers to develop and deliver new products and services. This trend is likely to continue in 2024, as healthcare providers recognize the need to adopt new technologies to improve the quality and efficiency of care. Here are some specific examples of HealthTech trends that we may see in the Middle East in 2024: The rise of wearable devices and fitness tracking apps: Wearable devices and fitness tracking apps can help people to monitor their health and fitness levels. This is particularly important in the Middle East, where obesity and other lifestyle-related diseases are on the rise. In 2024, we can expect to see more Middle Eastern healthtech startups developing and launching wearable devices and fitness tracking apps. The development of new telemedicine platforms: Telemedicine platforms allow patients to receive healthcare services remotely, via video conferencing or other digital channels. This is particularly important in the Middle East, where many people live in remote areas with limited access to healthcare facilities. In 2024, we can expect to see more Middle Eastern healthtech startups developing and launching telemedicine platforms. The use of AI to improve the efficiency of Middle Eastern healthcare systems: AI can be used to improve the efficiency of Middle Eastern healthcare systems in a variety of ways, such as by automating tasks and providing clinicians with insights into patient data. This is particularly important in the Middle East, where healthcare systems are often under-resourced. In 2024, we can expect to see even greater adoption of AI in healthcare systems across the Middle East. The development of new AI-powered diagnostic tools: AI-powered diagnostic tools can help clinicians to diagnose diseases more accurately and efficiently. This is particularly important in the Middle East, where there is a shortage of qualified healthcare professionals. In 2024, we can expect to see more Middle Eastern healthtech startups developing and launching new AI-powered diagnostic tools. The growth of the Middle Eastern e-pharmacy market: The Middle Eastern e-pharmacy market is expected to grow rapidly in the coming years. This will create new opportunities for Middle Eastern healthtech startups to develop and launch products and services that support the e-pharmacy industry. For example, healthtech startups could develop new ways to deliver prescription drugs or provide patients with insights into their medication usage. Overall, the Middle East HealthTech landscape is expected to grow and evolve rapidly in 2024. We can expect to see more investment in the sector, the development of new and innovative healthtech products and services, and the increased adoption of healthtech by traditional healthcare providers. Africa Predictions for the African healthtech landscape in 2024: Increased investment in African healthtech startups: The African healthtech sector is attracting increasing investment from both local and international investors. This is likely to continue in 2024, as investors recognize the potential of African healthtech startups to address the continent's healthcare challenges. More focus on mobile health solutions: Mobile health (mHealth) solutions are becoming increasingly popular in Africa, as they provide a convenient and affordable way to access healthcare services. In 2024, we can expect to see more African healthtech startups developing and launching mHealth solutions for a variety of conditions. Greater adoption of artificial intelligence (AI) in African healthcare: AI is already being used in healthcare in Africa in a variety of ways, such as for diagnosing diseases, developing new treatments, and improving the efficiency of healthcare systems. In 2024, we can expect to see even greater adoption of AI in African healthcare, including in the healthtech sector. More collaboration between African healthtech startups and traditional healthcare providers:African healthtech startups are increasingly collaborating with traditional healthcare providers to develop and deliver new products and services. This trend is likely to continue in 2024, as healthcare providers recognize the need to adopt new technologies to improve the quality and efficiency of care. Here are some specific examples of healthtech trends that we may see in Africa in 2024: The rise of telemedicine in Africa: Telemedicine allows patients to receive healthcare services remotely, via video conferencing or other digital channels. This is particularly important in Africa, where many people live in rural areas with limited access to healthcare facilities. In 2024, we can expect to see more African healthtech startups developing and launching telemedicine platforms. The development of new mHealth solutions for African diseases: MHealth solutions can be used to address a variety of African diseases, such as malaria, HIV/AIDS, and tuberculosis. In 2024, we can expect to see more African healthtech startups developing and launching mHealth solutions for these and other diseases. The use of AI to improve the efficiency of African healthcare systems: AI can be used to improve the efficiency of African healthcare systems in a variety of ways, such as by automating tasks and providing clinicians with insights into patient data. This is particularly important in Africa, where healthcare systems are often under-resourced. In 2024, we can expect to see even greater adoption of AI in healthcare systems across Africa. The development of new AI-powered diagnostic tools for African diseases: AI-powered diagnostic tools can help clinicians to diagnose African diseases more accurately and efficiently. This is particularly important for diseases such as malaria and tuberculosis, which can be difficult to diagnose using traditional methods. In 2024, we can expect to see more African healthtech startups developing and launching new AI-powered diagnostic tools for these and other diseases. The growth of the African health insurance market: The African health insurance market is expected to grow rapidly in the coming years. This will create new opportunities for African healthtech startups to develop and launch products and services that support the health insurance industry. For example, healthtech startups could develop new ways to administer health insurance claims or provide health insurers with insights into their members' health data. Overall, the African healthtech landscape is expected to grow and evolve rapidly in 2024. We can expect to see more investment in the sector, the development of new and innovative HealthTech products and services, and the increased adoption of HealthTech by traditional healthcare providers. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Exec Summary The J.P. Morgan Global Healthcare Conference is one of the most prestigious healthcare conferences in the world. It is attended by thousands of investors, analysts, and healthcare executives from around the globe. The conference provides a platform for companies to present their latest developments and strategies to investors. The 2024 J.P. Morgan Global Healthcare Conference will likely focus on a number of key trends and topics, including: The future of drug discovery and development: The pharmaceutical industry is undergoing a major transformation, with new technologies such as artificial intelligence (AI) and machine learning (ML) playing an increasingly important role in drug discovery and development. The conference is likely to feature discussions on the latest trends in drug discovery and development, as well as the impact of new technologies on the industry. The rise of personalized medicine: Personalized medicine is an approach to healthcare that takes into account individual genetic, environmental, and lifestyle factors to provide the best possible care for each patient. The conference is likely to feature discussions on the latest advances in personalised medicine, as well as the challenges and opportunities of implementing personalised medicine on a large scale. The impact of digital health: Digital health technologies are transforming the way healthcare is delivered. The conference is likely to feature discussions on the latest digital health trends, as well as the impact of digital health on the pharmaceutical industry and the overall healthcare system. The global healthcare landscape: The global healthcare landscape is changing rapidly, with new challenges and opportunities emerging in different parts of the world. The conference is likely to feature discussions on the key trends and developments in different regions, as well as the implications for the pharmaceutical industry. The increasing role of the consumer in healthcare: Consumers are playing an increasingly active role in their own healthcare. The conference is likely to feature discussions on the latest trends in consumer-centered healthcare, such as the use of wearable devices and telemedicine. The impact of artificial intelligence on healthcare: Artificial intelligence is having a major impact on many industries, including healthcare. The conference is likely to feature discussions on the latest trends in AI in healthcare, such as the use of AI to develop new drugs and therapies and to improve the efficiency of healthcare delivery. Source: https://www.jpmorgan.com/solutions/cib/insights/healthcare-conference-highlights One of the most prestigious healthcare conferences in the world. The J.P. Morgan Global Healthcare Conference is one of the most prestigious healthcare conferences in the world. It is attended by thousands of investors, analysts, and healthcare executives from around the globe. The conference provides a platform for companies to present their latest developments and strategies to investors. There are several reasons why the J.P. Morgan Global Healthcare Conference is so prestigious: It is organized by one of the world's leading investment banks. J.P. Morgan is a global leader in financial services, and its healthcare investment banking team is one of the most respected in the industry. This gives the conference a high level of credibility and prestige. It attracts a high-level audience. The conference is attended by some of the most influential investors and analysts in the healthcare sector. This gives companies a unique opportunity to reach a large audience of potential investors and partners. It is a forum for the latest innovations and trends in healthcare. The conference features presentations from leading healthcare companies, as well as panels and discussions on the latest trends in the industry. This gives attendees the opportunity to learn about the latest developments in healthcare and to network with other industry leaders. The J.P. Morgan Global Healthcare Conference is an important event for the healthcare industry. It provides a platform for companies to present their latest developments and strategies to investors, and it is a forum for the latest innovations and trends in healthcare. Here are some additional reasons why the J.P. Morgan Global Healthcare Conference is so prestigious: It has a long and successful history. The conference was first held in 1999, and it has grown to become one of the largest and most influential healthcare conferences in the world. It is well-organized and efficient. The conference is well-run, with a clear agenda and a schedule that allows attendees to maximize their time. It is a valuable networking opportunity. The conference brings together a large number of healthcare professionals, investors, and analysts, making it a great place to meet and network with people in the industry. Overall, the J.P. Morgan Global Healthcare Conference is a prestigious event because it is organised by a leading investment bank, attracts a high-level audience, and is a forum for the latest innovations and trends in healthcare. Source: https://www.jpmorgan.com/solutions/cib/insights/healthcare-conference-highlights Key talking points at the J.P. Morgan Global Healthcare Conference 2024? The J.P. Morgan Global Healthcare Conference 2024 is a major event in the healthcare industry, and it is likely to cover a wide range of topics. However, based on the current trends in the industry, here are some of the key talking points that are likely to be discussed at the conference: Precision medicine: Precision medicine is a new approach to healthcare that uses genetic and molecular information to tailor treatments to individual patients. This is a rapidly growing field with the potential to revolutionize the way we treat diseases. Data and analytics: Data and analytics are playing an increasingly important role in the healthcare industry. Companies are using data to develop new drugs and treatments, improve patient care, and reduce costs. Consumer health: Consumer health is another growing trend in the healthcare industry. Consumers are becoming more proactive about their health and are looking for ways to stay healthy and manage chronic conditions. Value-based care: Value-based care is a new model of healthcare that focuses on providing high-quality care at a lower cost. This is a top priority for healthcare payers, and it is likely to be a major topic of discussion at the conference. Emerging technologies: There are a number of emerging technologies that are having a major impact on the healthcare industry. These technologies include artificial intelligence, machine learning, and blockchain. In addition to these broad topics, the conference is also likely to feature discussions on specific areas of healthcare, such as oncology, cardiology, and neurology. There will also be presentations from leading healthcare companies, investors, and analysts. The J.P. Morgan Global Healthcare Conference 2024 is a must-attend event for anyone who is interested in the future of healthcare. The conference provides an opportunity to learn about the latest trends and innovations in the sector, and to network with other industry leaders. Final Thoughts Potential big news stories that could break at the J.P. Morgan Global Healthcare Conference in January 2024 include: A major pharmaceutical company could announce a breakthrough new drug or therapy. The conference is a major platform for pharmaceutical companies to announce their latest developments, and it is possible that a major company could announce a breakthrough new drug or therapy at the event. A digital health company could announce a major new partnership or investment. Digital health is one of the most rapidly growing sectors in healthcare, and it is likely that a major digital health company could announce a major new partnership or investment at the conference. A healthcare provider could announce a major new initiative to improve access or quality of care. The conference is also a platform for healthcare providers to announce new initiatives, and it is possible that a major provider could announce a major new initiative to improve access or quality of care at the event. A government agency could announce a new policy or initiative related to healthcare. The conference is also attended by government officials, and it is possible that a government agency could announce a new policy or initiative related to healthcare at the event. In addition to these specific news stories, the conference is also likely to feature a number of announcements about new research findings, clinical trial results, and other developments in the healthcare industry. Here are some more specific examples of potential big news stories that could break at the conference: A pharmaceutical company could announce the approval of a new drug for a major disease, such as cancer or Alzheimer's disease. A digital health company could announce a new partnership with a major healthcare provider to develop and implement new digital health solutions. A healthcare provider could announce a new initiative to improve access to healthcare in underserved communities. A government agency could announce a new policy to lower the cost of prescription drugs or to expand access to health insurance. The J.P. Morgan Global Healthcare Conference is a major event for the healthcare industry, and it is a likely place for big news stories to break. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Exec Summary The average multiples in HealthTech M&A deals in FY 2022 and Q1 2023 were: Enterprise value (EV) to sales: 5.6x EV to EBITDA: 12.5x These multiples were up from the previous year, when they were 3.6x and 11.5x, respectively. The increase in multiples was driven by a number of factors, including: The continued growth of the healthtech sector The increasing demand for digital health solutions The need for healthcare providers to improve efficiency and reduce costs However, multiples have started to decline in 2023, as investors become more cautious about the healthtech sector. As of March 2023, the average EV to sales multiple is 4.8x and the average EV to EBITDA multiple is 11.0x. The following factors are likely to continue to impact healthtech M&A multiples in 2023: The pace of growth in the healthtech sector The demand for digital health solutions The need for healthcare providers to improve efficiency and reduce costs The regulatory environment The overall economic climate It is important to note that multiples can vary significantly depending on the specific company and deal. Buyers will typically pay a premium for companies with strong growth prospects, a differentiated product or service offering, and a large addressable market. Buyers will also be more willing to pay a premium for companies that can help them achieve their strategic goals. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk HealthTech M&A transactions HealthTech M&A transactions can vary significantly in terms of size, nature, and market conditions. The multiples, or valuation metrics, used in these transactions are typically based on factors such as revenue, earnings, or users/subscribers, and can differ based on the company's stage of development, growth prospects, market position, and other relevant factors. Revenue Multiples: One commonly used metric is the revenue multiple, which measures the value of a company relative to its revenue. In HealthTech, revenue multiples can range widely depending on factors such as the company's growth rate, profitability, and competitive landscape. In the past, revenue multiples for HealthTech companies have ranged from 1x to 10x or more, with some highly valued companies commanding even higher multiples. Earnings Multiples: Another metric used in M&A transactions is the earnings multiple, which compares a company's valuation to its earnings (e.g., EBITDA - Earnings Before Interest, Taxes, Depreciation, and Amortization). Earnings multiples for HealthTech companies can vary based on factors such as profitability, growth potential, and industry trends. The range of earnings multiples in the HealthTech sector has historically been broad, spanning from single-digit multiples to higher double-digit or triple-digit multiples for high-growth, high-margin companies. User/Subscriber Multiples: In some cases, HealthTech companies with user-focused business models, such as telemedicine or digital health platforms, may be valued based on the number of users or subscribers they have acquired. Valuations based on these metrics can vary significantly depending on the size of the user base, user engagement, revenue per user, and other factors. While there isn't a fixed average multiple for user/subscriber-based valuations in HealthTech M&A, they can range from a few dollars per user to several hundred or even thousands of dollars per user, depending on the company's unique circumstances. Biggest HealthTech M&A deals 2023 Here are some of the biggest HealthTech M&A deals in 2023: 1) Amazon's acquisition of One Medical: Amazon announced in January 2023 that it would acquire One Medical, a telehealth company, for $3.9 billion. The deal will give Amazon a major foothold in the growing telehealth market. The deal closed on February 22, 2023. One Medical has over 190 locations in the United States and has over 700,000 members. The acquisition will give Amazon a major foothold in the primary care market. Amazon has been expanding its healthcare business in recent years. In 2018, it acquired PillPack, an online pharmacy. Amazon is also working on a number of other healthcare initiatives, including a virtual care service and a program to help employees find and book appointments with doctors. 2) UnitedHealth's acquisition of LHC Group: UnitedHealth announced in February 2023 that it would acquire LHC Group, a home health care company, for $5.4 billion. The deal will give UnitedHealth a larger presence in the home health care market. LHC Group has over 125,000 employees and provides home health care services to over 100,000 patients in 39 states. UnitedHealth is the largest health insurer in the United States. The acquisition will give UnitedHealth a larger presence in the home health care market. UnitedHealth has been expanding its healthcare business in recent years. In 2019, it acquired Change Healthcare, a healthcare IT company. UnitedHealth is also working on a number of other healthcare initiatives, including a virtual care service and a program to help employees find and book appointments with doctors. The acquisition of LHC Group is a significant move by UnitedHealth into the home health care market. It will be interesting to see how UnitedHealth integrates LHC Group into its existing healthcare businesses and how it plans to use LHC Group's platform to expand its reach into the home health care market. Here are some of the potential benefits of the acquisition for UnitedHealth: Increased market share: The acquisition will give UnitedHealth a larger presence in the home health care market, which is a growing industry. Improved efficiency: UnitedHealth can combine LHC Group's operations with its own to improve efficiency and reduce costs. New products and services: UnitedHealth can use LHC Group's expertise to develop new products and services for its customers. Improved customer experience: UnitedHealth can use LHC Group's network of providers to improve the customer experience for its home health care customers. However, there are also some potential risks associated with the acquisition: Regulatory scrutiny: The acquisition could face regulatory scrutiny from the U.S. Department of Justice or other antitrust authorities. Integration challenges: UnitedHealth may face challenges integrating LHC Group's operations into its own. Financial risks: The acquisition could be dilutive to UnitedHealth's earnings in the near term. Overall, the acquisition of LHC Group is a strategic move by UnitedHealth to expand its presence in the home health care market. The acquisition could have a number of benefits for UnitedHealth, but there are also some potential risks associated with the deal. 3) Johnson & Johnson's acquisition of Auris Medical: Johnson & Johnson announced in March 2023 that it would acquire Auris Medical, a company developing a treatment for hearing loss, for $3.9 billion. The deal will give Johnson & Johnson a new product in its portfolio. Auris Medical is a privately held company that is developing a treatment for hearing loss. The acquisition is part of J&J's strategy to expand its presence in the medical devices market. Auris Medical's lead product is the AurAlign system, which is a minimally invasive surgical device that is designed to restore hearing in patients with severe to profound hearing loss. The system is still in the clinical trial phase, but it has the potential to be a major breakthrough in the treatment of hearing loss. J&J believes that the acquisition of Auris Medical will give it a leading position in the emerging market for hearing loss treatments. The global market for hearing loss devices is expected to reach $10 billion by 2025. J&J also believes that the AurAlign system could be used to treat other conditions, such as vestibular disorders and sleep apnea. The acquisition of Auris Medical is a significant move by J&J to expand its presence in the medical devices market. The deal is also a sign of J&J's commitment to developing new treatments for serious medical conditions. Here are some of the potential benefits of the acquisition for J&J: Increased market share: The acquisition will give J&J a leading position in the emerging market for hearing loss treatments. New product pipeline: Auris Medical has a number of other products in development, which could provide J&J with new revenue streams. Strengthened research and development capabilities: Auris Medical has a strong research and development team, which could help J&J to develop new products and technologies. However, there are also some potential risks associated with the acquisition: Regulatory scrutiny: The acquisition could face regulatory scrutiny from the U.S. Food and Drug Administration (FDA) or other regulatory authorities. Integration challenges: J&J may face challenges integrating Auris Medical's operations into its own. Financial risks: The acquisition could be dilutive to J&J's earnings in the near term. Overall, the acquisition of Auris Medical is a strategic move by J&J to expand its presence in the medical devices market. The acquisition could have a number of benefits for J&J, but there are also some potential risks associated with the deal. 4) Thoma Bravo's acquisition of Kareo: Thoma Bravo, a private equity firm, announced in April 2023 that it would acquire Kareo, a healthcare software company, for $5.7 billion. The deal will give Thoma Bravo a leading position in the healthcare software market. Kareo provides cloud-based software solutions for medical practices, including electronic health records (EHRs), practice management, and patient engagement tools. The company has over 20,000 customers in the United States and Canada. Thoma Bravo is a leading private equity firm that specializes in investing in software and technology companies. The acquisition of Kareo is a significant move by Thoma Bravo to expand its presence in the healthcare software market. The deal is also a sign of Thoma Bravo's confidence in the growth prospects of the healthcare software market. Here are some of the potential benefits of the acquisition for Thoma Bravo: Increased market share: The acquisition will give Thoma Bravo a leading position in the healthcare software market. New product pipeline: Kareo has a number of new products in development, which could provide Thoma Bravo with new revenue streams. Strengthened research and development capabilities: Kareo has a strong research and development team, which could help Thoma Bravo to develop new products and technologies. However, there are also some potential risks associated with the acquisition: Regulatory scrutiny: The acquisition could face regulatory scrutiny from the U.S. Food and Drug Administration (FDA) or other regulatory authorities. Integration challenges: Thoma Bravo may face challenges integrating Kareo's operations into its own. Financial risks: The acquisition could be dilutive to Thoma Bravo's earnings in the near term. Overall, the acquisition of Kareo is a strategic move by Thoma Bravo to expand its presence in the healthcare software market. The acquisition could have a number of benefits for Thoma Bravo, but there are also some potential risks associated with the deal. Here are some of the key reasons why Thoma Bravo acquired Kareo: Kareo is a leading provider of cloud-based healthcare software solutions. The company has a strong track record of innovation and growth, and it is well-positioned to benefit from the continued adoption of cloud-based healthcare solutions. The healthcare software market is a large and growing market. The global market for healthcare software is expected to reach $250 billion by 2025. Thoma Bravo has a strong track record of investing in and growing healthcare software companies. The firm has invested in a number of successful healthcare software companies, including Practice Fusion, Athenahealth, and Allscripts. The acquisition of Kareo is a significant development in the healthcare software market. It is a sign of the continued growth of the market, and it is a vote of confidence in the future of cloud-based healthcare solutions. These are just a few of the many healthtech M&A deals that have been announced in 2023. The healthtech sector is expected to continue to see strong M&A activity in the coming years, as companies look to expand their reach, develop new products and services, and improve their competitive position. Future of HealthTech M&A The future of HealthTech M&A in the next 12 months is expected to be strong, as companies look to expand their reach, develop new products and services, and improve their competitive position. Here are some of the key trends that are expected to drive healthtech M&A in the next 12 months: The continued growth of the healthcare industry: The global healthcare industry is expected to reach $10 trillion by 2025. This growth is being driven by a number of factors, including an aging population, the rise of chronic diseases, and the increasing adoption of new technologies. The need for innovation: The healthcare industry is facing a number of challenges, including rising costs, a shortage of healthcare workers, and the need to improve patient outcomes. Companies are looking to M&A as a way to acquire new technologies and capabilities that can help them address these challenges. The rise of digital health: Digital health is transforming the healthcare industry. Companies are looking to M&A as a way to acquire new digital health technologies and capabilities that can help them improve patient care and efficiency. Some of the specific areas of healthtech that are expected to see strong M&A activity in the next 12 months include: Telehealth: Telehealth is a rapidly growing market. Companies are looking to M&A as a way to acquire new telehealth technologies and capabilities that can help them expand their reach and improve patient care. Healthcare IT: Healthcare IT is another rapidly growing market. Companies are looking to M&A as a way to acquire new healthcare IT technologies and capabilities that can help them improve efficiency and reduce costs. Digital health: Digital health is a broad area that includes a number of different technologies, such as wearables, mobile health apps, and electronic health records (EHRs). Companies are looking to M&A as a way to acquire new digital health technologies and capabilities that can help them improve patient care and efficiency. The future of healthtech M&A is expected to be strong in the next 12 months. Companies are looking to M&A as a way to expand their reach, develop new products and services, and improve their competitive position. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk